Bruker Co. (NASDAQ:BRKR) Receives $70.50 Average PT from Analysts

Shares of Bruker Co. (NASDAQ:BRKR) have been assigned a consensus recommendation of “Moderate Buy” from the eleven ratings firms that are currently covering the stock, Marketbeat.com reports. Five analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $66.50.

A number of brokerages recently weighed in on BRKR. Guggenheim restated a “buy” rating on shares of Bruker in a report on Monday, February 24th. Stifel Nicolaus cut their price objective on Bruker from $70.00 to $57.00 and set a “hold” rating on the stock in a research report on Friday, February 14th. Barclays decreased their target price on Bruker from $60.00 to $50.00 and set an “overweight” rating for the company in a report on Thursday. Citigroup cut their price target on Bruker from $75.00 to $50.00 and set a “buy” rating on the stock in a report on Monday, April 7th. Finally, Bank of America lifted their price objective on Bruker from $78.00 to $80.00 and gave the company a “buy” rating in a research note on Friday, December 13th.

Bruker Price Performance

NASDAQ:BRKR opened at $38.76 on Monday. Bruker has a 52 week low of $34.10 and a 52 week high of $90.03. The stock’s fifty day moving average is $46.16 and its two-hundred day moving average is $54.75. The company has a market capitalization of $5.88 billion, a P/E ratio of 51.00, a P/E/G ratio of 2.16 and a beta of 1.18. The company has a quick ratio of 0.77, a current ratio of 1.60 and a debt-to-equity ratio of 1.15.

Bruker (NASDAQ:BRKR) last released its quarterly earnings results on Thursday, February 13th. The medical research company reported $0.76 EPS for the quarter, topping analysts’ consensus estimates of $0.75 by $0.01. Bruker had a return on equity of 21.01% and a net margin of 3.36%. Equities analysts expect that Bruker will post 2.69 EPS for the current year.

Bruker Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, March 28th. Shareholders of record on Monday, March 17th were paid a $0.05 dividend. The ex-dividend date was Monday, March 17th. This represents a $0.20 annualized dividend and a yield of 0.52%. Bruker’s dividend payout ratio is currently 26.32%.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Alpha Wealth Funds LLC purchased a new stake in Bruker in the first quarter valued at $230,000. CGN Advisors LLC increased its position in shares of Bruker by 1.4% during the first quarter. CGN Advisors LLC now owns 22,014 shares of the medical research company’s stock worth $919,000 after purchasing an additional 296 shares in the last quarter. Merit Financial Group LLC lifted its holdings in shares of Bruker by 226.9% in the 1st quarter. Merit Financial Group LLC now owns 16,722 shares of the medical research company’s stock valued at $698,000 after purchasing an additional 11,607 shares during the last quarter. Rhumbline Advisers boosted its position in shares of Bruker by 1.2% in the 1st quarter. Rhumbline Advisers now owns 317,267 shares of the medical research company’s stock valued at $13,243,000 after purchasing an additional 3,763 shares during the period. Finally, GAMMA Investing LLC grew its stake in Bruker by 4,299.2% during the 1st quarter. GAMMA Investing LLC now owns 56,266 shares of the medical research company’s stock worth $2,349,000 after buying an additional 54,987 shares during the last quarter. Institutional investors and hedge funds own 79.52% of the company’s stock.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.